article thumbnail

AbbVie CEO looks like a fool before Congress

World of DTC Marketing

According to CNBC “AbbVie workers say they worry that the company is putting profits ahead of safety and the health of its U.S. The cost of Humira, which is injected via syringe, was more than $72,000 a year on prescription drug websites this week and is not expected to come down until at least 2023. Why the increase?

Pharma 181
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf. 1435 (“Affordable Prescriptions for Patients Act of 2021”), [link] gov/bill/117th-congress/senate-bill/1435/text; H.R. Actavis, 570 U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Medgadget

She started working on this technology around 2013 after realizing the dire need for an alternative solution for mental disorders, and through realization that science can provide more answers. During this time, two additional studies ended successfully and were published, further validating the clinical safety and effectiveness.

article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

From 1990 through 2013, the FDA approved 131 FDC products, on average 5.7 Improved convenience and safety. Replacing two or three pills with a single FDC drug product also translates into less time spent filling (and refilling) prescriptions. More FDC products flowing into pharma pipelines. The numbers tell the story.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

Since the publication of the fifth Diagnostic and Statistical Manual of Mental Disorders in 2013, both conditions are grouped under the term FSIAD, which includes reduced arousal and interest. One Phase II trial was completed back in 2013, as per ClinicalTrials.gov.